|

Relugolix Clinical Trials

11 actively recruiting trials across 9 locations

Also known as: N-(4-(1-((2,6-Difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxyurea, Orgovyx, Relumina, TAK 385, TAK-385 +3 more

Pipeline

Phase 1: 1Phase 2: 6Phase 3: 4

Top Sponsors

  • NRG Oncology2
  • Mayo Clinic2
  • Qilu Pharmaceutical Co., Ltd.1
  • Ohio State University Comprehensive Cancer Center1
  • Northwestern University1

Indications

  • Cancer11
  • Prostate Adenocarcinoma6
  • Heart Disease2
  • Stage IIC Prostate Cancer AJCC v82
  • Biochemically Recurrent Prostate Carcinoma2

Phoenix, Arizona2 trials

Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial

Mayo Clinic in Arizona

Phase 2
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study

Cancer Center at Saint Joseph's

Phase 2

Other1 trial

Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Phase 3

Birmingham, Alabama1 trial

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

University of Alabama at Birmingham Cancer Center

Phase 3

Anchorage, Alaska1 trial

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

Anchorage Associates in Radiation Medicine

Phase 3

Scottsdale, Arizona1 trial

Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial

Mayo Clinic in Arizona

Phase 2

Orlando, Florida1 trial

Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer

AdventHealth Orlando

Phase 1

Atlanta, Georgia1 trial

REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial

Emory Proton Therapy Center

Phase 3

Chicago, Illinois1 trial

Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial

Northwestern University

Phase 2

Boston, Massachusetts1 trial

RecoverPC: Relugolix vs GnRH Agonist in Quality of Life

Brigham and Women's Hospital

Phase 2

Columbus, Ohio1 trial

Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer

Ohio State University Comprehensive Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.